Compare ALMU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALMU | CHRS |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.6M | 296.8M |
| IPO Year | N/A | 2014 |
| Metric | ALMU | CHRS |
|---|---|---|
| Price | $21.79 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $24.67 | $5.51 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.49 | $73.08 |
| Revenue Next Year | $60.61 | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.20 | $0.72 |
| 52 Week High | $31.79 | $2.62 |
| Indicator | ALMU | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 44.31 |
| Support Level | $14.16 | $1.55 |
| Resistance Level | $22.12 | $1.80 |
| Average True Range (ATR) | 3.44 | 0.11 |
| MACD | -0.65 | 0.00 |
| Stochastic Oscillator | 22.23 | 20.93 |
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.